Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. - Wikidata - wikimedia - TriplyDB

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

http://www.wikidata.org/entity/Q37613957

about

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas Recent Molecular Advances in Our Understanding of Glioma Oligodendroglioma: pathology, molecular mechanisms and markers IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives IDH mutations may not preclude distant, trans-tentorial spread in gliomas: a case report and review of the literature Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation Emerging targeted therapies for glioma.Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.IDH mutations: genotype-phenotype correlation and prognostic impact.IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.Actionable molecular biomarkers in primary brain tumors.Genetic landscape of extreme responders with anaplastic oligodendroglioma.Does early resection of presumed low-grade glioma improve survival? A clinical perspective.A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions.IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.Combination genetic signature stratifies lower-grade gliomas better than histological grade.Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.A malignant cellular network in gliomas: potential clinical implications.Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas.Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.Chemotherapy in glioma.

P2860

Q24194645-1B05EF7E-8EC9-4F2D-87F8-A5697061BE98 Q26798442-CCD1139E-4C3C-4FE6-B538-633587D8E4C3 Q27002448-1454CB23-62DA-4320-BE12-4BCB6AD11D8B Q28066926-991044B9-142E-4130-A8BB-5D41B806C3CC Q28075869-817ABAE6-8FB9-4620-BEA2-FA1CD3A709A5 Q28383205-13D3F4A7-E753-4BEC-BBA8-C7BB33F76F5C Q28396617-83DFDCC3-D1BA-4A8C-9941-AC7DA9E7459D Q30241853-40787E63-1998-4C92-BB97-85DDBE05039A Q30458648-3282EB0B-93D1-4B80-92D8-C202CB2FF7F2 Q33419628-F8A829EC-AB87-48BA-A502-2FCF2FA29A9B Q33439379-360ED506-C407-406E-8477-63A4DCAB3A3B Q33615867-78C10AC8-D79F-4FDF-9541-F0E2D8797D51 Q33660428-C74C93E4-DCAD-440A-A711-D919CA7C9760 Q33698756-DD80F49F-E20E-40D6-83DA-1657EBB95278 Q33772355-F81BAAA6-79E1-44F1-B8E8-AF1E026C98BE Q33829209-F644F783-1362-4970-9429-32A1B60D60FE Q33867304-778F4770-63BE-4925-8142-6E2DCA17DD99 Q34501052-079DB70B-9B9D-4746-8A2C-95D60599C30D Q34511752-54C4AFCA-115F-419A-ACB5-9E861FE665DE Q34604438-B4158E6C-1187-4591-9833-E89660DFFFBA Q35204658-215CBE9B-432B-44D5-903F-B02D9FBE908D Q35811255-A480C80D-C8F4-48F6-8F47-F7D36A050605 Q36037100-972037C9-0B59-4E8F-A83B-09C11ECF51D5 Q36096036-1E5F15A3-E6B8-4300-8D0E-BC3803380561 Q36356194-79497869-139F-4439-9512-C699CDD45EAD Q36385589-DF5ECC52-5FAB-49AE-9087-7CEC20EC1403 Q36413047-EAE37ABB-CEF9-4149-B0BB-9CFEDA32588D Q36557573-F2860E84-5FD6-458A-9E46-18288B8E0D6F Q36559617-2C230863-48E8-4735-A4E7-2C81EB44CC6A Q36618241-B7FAD2BE-9490-45EC-A29A-443A0588D273 Q36705939-79D376EB-EC0A-4DA4-8260-6D1DA7D10F62 Q36759382-782984DD-3830-4451-A330-615980A7B704 Q36809370-4492D452-3942-45E5-A39E-F9D4B23D58BF Q36819744-96AF0685-1A4C-45A1-8C7F-19862BAB6168 Q37086042-D4CB3107-C02C-4362-A3FF-38012557734E Q37518265-AA21A859-4ABB-4222-A4B2-5EAEE8258160 Q37662100-A73810FE-ACED-4307-8D77-042ABA9B92BA Q37716625-BACE2279-F9CE-4B4D-935A-00AF17814862 Q38405744-1641226E-E394-4282-8E49-5516E4AB8EF8 Q38438439-E180A948-EFBE-4C1F-93DF-0699273A5A00

P2860

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

http://www.wikidata.org/entity/Q37613957

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Benefit from procarbazine, lom ...... sociated with mutation of IDH.

@en

Benefit from procarbazine, lom ...... sociated with mutation of IDH.

@nl

type

label

Benefit from procarbazine, lom ...... sociated with mutation of IDH.

@en

Benefit from procarbazine, lom ...... sociated with mutation of IDH.

@nl

prefLabel

Benefit from procarbazine, lom ...... sociated with mutation of IDH.

@en

Benefit from procarbazine, lom ...... sociated with mutation of IDH.

@nl

P1433

Q37613957-9C5D6F76-23F9-42CF-B52B-DA5AE3B36B10

P1476

Q37613957-6BDBA016-485F-49ED-847F-55B49EF71539

P2093

Q37613957-2375D5E1-8979-425C-ACF4-CA63AF9508BB

Q37613957-497EA6F4-D507-42E8-8A5C-7BA0D70393AB

Q37613957-527AB50D-E0AD-4495-8980-EF309E838397

Q37613957-84ADDB00-AB3D-4162-88D7-95394C295A86

Q37613957-959E79CB-45B2-4314-B1E9-26582D1C360A

Q37613957-AC8770E9-9428-4758-A8A1-C84DBE8EFE9E

Q37613957-C603AA95-4237-4996-B21D-D74D133C82A6

Q37613957-D6B5D623-3D79-4613-A561-78E918F2ADCD

Q37613957-E3E4AF3B-AE5B-4B07-BC08-92A337E4D15E

Q37613957-E4DB939F-A3E5-4ED7-8487-0586C0CB1255

P2860

Q37613957-0233DEB5-42B6-4907-B196-D764C36372EF

Q37613957-0274436A-A0D3-43BE-A9CC-3E39B96BB9F7

Q37613957-0553CE23-837E-4A4E-A571-1C7BE9F701CD

Q37613957-0B5A00A6-DC49-4A5E-92F5-4D481AE35C36

Q37613957-0C7DF9BE-D847-4769-8513-E84E479FB736

Q37613957-0F093E71-9F05-445F-AC70-45C9B8083114

Q37613957-104B57A8-17F9-45B9-9A7E-E95D45A7AA0C

Q37613957-199649BF-F9BB-48C7-B988-6E12436BCB46

Q37613957-1AD42F6D-3D19-4FE2-B2AF-0121FFC2F8AC

Q37613957-27F3B6A1-031C-40A9-90FF-DC9250AA92FA

P304

Q37613957-A9CA7D55-2423-4859-A444-BD7F6F45ED81

P31

Q37613957-6F6E1350-0764-4D17-84BA-4EB8D4C67152

P356

Q37613957-6625C07C-5711-4288-9C44-7037CD9C7F16

P407

Q37613957-439B2954-FB06-4133-AD14-B6164DD54270

P433

Q37613957-7420B6AD-F2EE-47A2-8454-96C29CEEAE74

P478

Q37613957-3725540B-66E8-4900-94EE-8538F23F6D0B

P50

Q37613957-693F76EE-C93B-4767-A0E2-46ACBEEB489C

Q37613957-B11EA0C6-F116-40B4-9328-7A7CB39CBD49

P577

Q37613957-F4BAB0C1-84DA-487B-A417-38319B64CCFF

P5875

Q37613957-C602EAD7-B616-476A-845C-5433A9D855B2

P698

Q37613957-437B1D23-673F-497D-976D-36F410756533

P921

Q37613957-67ADCE08-EDAA-4BE0-9791-7495F03BA1E2

Q37613957-9817A2D8-5106-4ADA-95BF-5ACDFCE0F65E

P932

Q37613957-D467EF8B-9A96-4A71-BB31-E908E0C30E7B

P356

JCO.2013.49.3726

P1433

Journal of Clinical Oncology

P1476

Benefit from procarbazine, lom ...... sociated with mutation of IDH.

@en

P2093

Caterina Giannini

http://www.w3.org/2001/XMLSchema#string

David G Brachman

http://www.w3.org/2001/XMLSchema#string

Edward G Shaw

http://www.w3.org/2001/XMLSchema#string

J Gregory Cairncross

http://www.w3.org/2001/XMLSchema#string

Jan C Buckner

http://www.w3.org/2001/XMLSchema#string

Jason T Huse

http://www.w3.org/2001/XMLSchema#string

Karen L Fink

http://www.w3.org/2001/XMLSchema#string

Luis Souhami

http://www.w3.org/2001/XMLSchema#string

Meihua Wang

http://www.w3.org/2001/XMLSchema#string

Robert B Jenkins

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

IDH1 and IDH2 mutations in gliomas

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

P304

783-790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.49.3726

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Normand J. Laperriere

P577

2014-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260154444

http://www.w3.org/2001/XMLSchema#string

P698

24516018

http://www.w3.org/2001/XMLSchema#string

P921

oligodendrocyte

P932

3940537

http://www.w3.org/2001/XMLSchema#string